Differential response to roflumilast in patients with chronic obstructive pulmonary disease: real-world evidence
CONCLUSIONS: The benefit of roflumilast in moderate-to-severe exacerbations was estimated to be greater in specific subgroups of patients with COPD. Personalised approaches to roflumilast based on clinical phenotypes would be effective for COPD.PMID:38505074 | PMC:PMC10944795 | DOI:10.21037/jtd-23-1129
Source: Journal of Thoracic Disease - Category: Respiratory Medicine Authors: Hyun Woo Lee Jiyu Sun Hyo-Jin Lee Jung-Kyu Lee Tae Yeon Park Eun Young Heo Chin Kook Rhee Deog Kyeom Kim Source Type: research